Literature DB >> 20485633

Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study.

Ki Tae Suk1, Moon Young Kim, Dong Hun Park, Kyu Hong Kim, Ki Won Jo, Jin Hon Hong, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Soon Koo Baik.   

Abstract

BACKGROUND/AIMS: Propranolol can prevent variceal bleeding by ameliorating portal hypertension. We conducted this study to determine the effect of propranolol on portal hypertension and the optimal required dose in Korean cirrhotic patients.
METHODS: This study prospectively evaluated 50 patients with cirrhosis who exhibited variceal bleeding. The hepatic venous pressure gradient (HVPG), portal venous flow, heart rate (HR), and blood pressure were assessed both at baseline and at 3 months after the treatment. The initial dose of propranolol (20 mg) was subsequently adjusted until the target HR was reached. Patients in whom HVPG reduced by >20% or to less than 12 mmHg were defined as responders.
RESULTS: Propranolol significantly (p<0.01) reduced the HVPG (-21+/-26%, mean+/-standard deviation), portal venous flow (-25+/-21%), HR (-20+/-13%), and blood pressure (-3+/-13%). Twenty-nine patients were responders, and the optimal required dose was 154.4 mg. The main complication was dizziness (24%), but this was not serious enough to require medication withdrawal.
CONCLUSIONS: Propranolol is safe and effective at reducing portal pressure in Korean cirrhotic patients. An effective improvement in portal hypertension requires the dose to be increased until the target HR is reached.

Entities:  

Keywords:  Liver cirrhosis; Portal hypertension; Pressure; Propranolol

Year:  2007        PMID: 20485633      PMCID: PMC2871621          DOI: 10.5009/gnl.2007.1.2.159

Source DB:  PubMed          Journal:  Gut Liver        ISSN: 1976-2283            Impact factor:   4.519


  19 in total

Review 1.  [Assessment and current treatment of portal hypertension].

Authors:  Soon Koo Baik
Journal:  Korean J Hepatol       Date:  2005-09

2.  [Pharmacological therapy of portal hypertension--focused on Korean data].

Authors:  Soon Koo Baik
Journal:  Korean J Gastroenterol       Date:  2005-06

3.  [Interequipment variability of Doppler ultrasonographic indices in patients with liver cirrhosis].

Authors:  Myeong Gwan Jee; Soon Koo Baik; Dong Hun Park; Moon Young Kim; Dae Wook Rhim; Ki Won Jo; Jin Hon Hong; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon
Journal:  Korean J Hepatol       Date:  2006-12

4.  Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study.

Authors:  Silvia Sookoian; María Alejandra Fernández; Gustavo Castaño
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

5.  Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites.

Authors:  H H Zhou; R P Koshakji; D J Silberstein; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

6.  Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis.

Authors:  Chii-Shyan Lay; Yang-Te Tsai; Fa-Yauh Lee; Yi-Liang Lai; Cheng-Ju Yu; Chih-Bin Chen; Cheng-Yuan Peng
Journal:  J Gastroenterol Hepatol       Date:  2006-02       Impact factor: 4.029

7.  Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: a prospective multicenter randomized trial.

Authors:  A Avgerinos; A Armonis; S Manolakopoulos; G Rekoumis; G Argirakis; N Viazis; J Vlachogiannakos; A Adamopoulos; T Kanaghinis; S A Raptis
Journal:  Gastrointest Endosc       Date:  2000-06       Impact factor: 9.427

8.  Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.

Authors:  Soon Koo Baik; Phil Ho Jeong; Sang Won Ji; Byung Su Yoo; Hyun Soo Kim; Dong Ki Lee; Sang Ok Kwon; Young Ju Kim; Joong Wha Park; Sei Jin Chang; Samuel S Lee
Journal:  Am J Gastroenterol       Date:  2005-03       Impact factor: 10.864

9.  Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.

Authors:  Juan Turnes; Juan Carlos Garcia-Pagan; Juan G Abraldes; Manuel Hernandez-Guerra; Alessandra Dell'Era; Jaime Bosch
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

10.  Racial differences in beta-adrenoceptor-mediated responsiveness.

Authors:  J A Johnson; B S Burlew; R N Stiles
Journal:  J Cardiovasc Pharmacol       Date:  1995-01       Impact factor: 3.105

View more
  9 in total

Review 1.  Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.

Authors:  Seong Hee Kang; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047

2.  β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.

Authors:  De-Run Kong; Jin-Guang Wang; Bin Sun; Ming-Quan Wang; Chen Chen; Fang-Fang Yu; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

3.  Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.

Authors:  Jae Hyun Kim; Jung Min Kim; Youn Zoo Cho; Ji Hoon Na; Hyun Sik Kim; Hyoun A Kim; Hye Won Kang; Soon Koo Baik; Sang Ok Kwon; Seung Hwan Cha; Young Ju Kim; Moon Young Kim
Journal:  Clin Mol Hepatol       Date:  2014-12-24

4.  Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?

Authors:  Tae Wan Kim; Hong Joo Kim; Chang Uk Chon; Hyun Sun Won; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Clin Mol Hepatol       Date:  2012-06-26

5.  Revision and update on clinical practice guideline for liver cirrhosis.

Authors:  Ki Tae Suk; Soon Koo Baik; Jung Hwan Yoon; Jae Youn Cheong; Yong Han Paik; Chang Hyeong Lee; Young Seok Kim; Jin Woo Lee; Dong Joon Kim; Sung Won Cho; Seong Gyu Hwang; Joo Hyun Sohn; Moon Young Kim; Young Bae Kim; Jae Geun Kim; Yong Kyun Cho; Moon Seok Choi; Hyung Joon Kim; Hyun Woong Lee; Seung Up Kim; Ja Kyung Kim; Jin Young Choi; Dae Won Jun; Won Young Tak; Byung Seok Lee; Byoung Kuk Jang; Woo Jin Chung; Hong Soo Kim; Jae Young Jang; Soung Won Jeong; Sang Gyune Kim; Oh Sang Kwon; Young Kul Jung; Won Hyeok Choe; June Sung Lee; In Hee Kim; Jae Jun Shim; Gab Jin Cheon; Si Hyun Bae; Yeon Seok Seo; Dae Hee Choi; Se Jin Jang
Journal:  Korean J Hepatol       Date:  2012-03-22

6.  Life-threatening bleeding from peristomal varices after cystoprostatectomy: multimodal approach in a cirrhotic, encephalopathic patient with severe portal hypertension.

Authors:  Sergej E L Staubli; Tobias Gramann; Christoph Schwab; David Semela; Lukas Hechelhammer; Daniel S Engeler; Hans-Peter Schmid; Dominik Abt; Livio Mordasini
Journal:  Case Rep Urol       Date:  2015-01-29

7.  Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis.

Authors:  Tzu-Hao Li; Yu-Lien Tsai; Chien-Fu Hsu; Chih-Wei Liu; Chia-Chang Huang; Ying-Ying Yang; Hung-Cheng Tsai; Shiang-Fen Huang; Yun-Cheng Hsieh; Hsuan-Miao Liu; Tzung-Yan Lee; Ming-Chih Hou; Chang-Youh Tsai; Han-Chieh Lin
Journal:  Gastroenterol Res Pract       Date:  2020-04-09       Impact factor: 2.260

Review 8.  Primary prophylaxis of variceal bleeding in patients with cirrhosis: A comparison of different strategies.

Authors:  Ângelo Zambam de Mattos; Carlos Terra; Alberto Queiroz Farias; Paulo Lisboa Bittencourt
Journal:  World J Gastrointest Endosc       Date:  2021-12-16

9.  Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients.

Authors:  Behzad Hatami; Sara Ashtari; Afsaneh Sharifian; Hamideh Rahmani Seraji; Elmira Khalili; Yasin Hatami; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.